Global cell therapy manufacturing market is estimated to be valued at USD 4.91 Bn in 2024, and is expected to exhibit a CAGR of 14.9% during the forecast period (2024-2031). Global cell therapy manufacturing market has been witnessing significant growth in the recent years, owing to growing prevalence of chronic diseases such as cancer and cardiac disorders. Cell therapies are more effective treatment options for various conditions as compared to traditional drugs. The advancement in cell therapy manufacturing technology and government support for cell-based research especially in the U.S. and Europe are projected to drive the market growth during the forecast period. However, high costs associated with cell therapy development and manufacturing can hamper the market growth.

Market Dynamics:

Global cell therapy manufacturing market growth is driven by growing prevalence of chronic diseases such as cancer and cardiac disorders. Advancements in cell therapy manufacturing technologies enable efficient and large-scale production, and this drives the market growth. Various governments across major markets are supporting cell-based research through funding and regulatory guidelines, and this offers opportunities for market players. However, high costs associated with cell therapy development from laboratory to commercialization can hamper the growth of market. Market players require huge capital investments, and this hampers the market growth. Lack of skilled professionals for cell processing also hampers the market growth. Ongoing mergers and acquisitions among players provides potential growth opportunities in the near future.

Key Features of the Study:

• This report provides an in-depth analysis of the global cell therapy manufacturing market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global cell therapy manufacturing market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this includes WuXi AppTec, Inc., Lineage Cell Therapeutics, Inc., Healios Ltd. , Lonza, Merck KGaA, Takara Bio Inc., Sumitomo Dainippon Pharma Co., LTD., Fujifilm Holdings Corporation, Thermo Fisher Scientific, Inc., Astellas Pharma Inc., OXGENE, Cytiva, Exothera, Charles River Laboratories, Cell Therapies Pty Ltd, Bio-Techne, Catalent, Inc
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global cell therapy manufacturing market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cell therapy manufacturing market.

Detailed Segmentation-

• By Therapy Type:
  • Allogeneic Cell Therapy
  • Autologous Cell Therapy
• By Technology Type:
  • Somatic Cell Technology
  • Cell Immortalization Technology
  • Viral Vector Technology
  • Genome Editing Technology
  • Cell Plasticity Technology
  • 3D Technology
• By Manufacturing Purpose:
  • Clinical
  • Commercial
  • Pre-clinical
• By Application:
  • Musculoskeletal
  • Cardiovascular
  • Gastrointestinal
  • Neurological
  • Oncology
  • Dermatology
  • Others
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa

Company Profiles:

• WuXi AppTec, Inc.
• Lineage Cell Therapeutics, Inc.
• Healios Ltd. 
• Lonza   
• Merck KGaA
• Takara Bio Inc.
• Sumitomo Dainippon Pharma Co., LTD. 
• Fujifilm Holdings Corporation 
• Thermo Fisher Scientific, Inc.
• Astellas Pharma Inc.
• OXGENE
• Cytiva
• Exothera
• Charles River Laboratories
• Cell Therapies Pty Ltd
• Bio-Techne
• Catalent, Inc